UniCoVac Position Paper: Considerations for University Campus-Based Programmes for COVID-19 and Other Infectious Disease Vaccines
LIAS Working Paper Series · 2021
DOI: 10.29311/lwps.202153849 ↗Kurz gefasst
Fachartikel in der Zeitschrift LIAS Working Paper Series, 2021. Verfasst von Christopher D Bayliss und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
This position paper sets out the rationale, logistics and limitations for delivery of COVID-19, MMR and meningitis vaccines to university students. Key aspects considered are ascertainment of vaccine status and campus-based delivery of vaccines. The approaches described in this position paper require an inter-disciplinary approach. There will be a requirement for data analysts to enable personalised, secure access to vaccination records, for social media experts and sociologists to design appropriate pathways and literature for disseminating information and for public health experts to oversee literature outputs and delivery of campus-based immunisation programmes. Contributions from vaccinologists, economists and modellers will also be required for monitoring and assessing the utility of implemented recommendations.
Zitieren
APA
Bayliss, C. D., Gies, L., & Pareek, M. (2021). UniCoVac Position Paper: Considerations for University Campus-Based Programmes for COVID-19 and Other Infectious Disease Vaccines. LIAS Working Paper Series. https://doi.org/10.29311/lwps.202153849
Vancouver
Bayliss CD, Gies L, Pareek M. UniCoVac Position Paper: Considerations for University Campus-Based Programmes for COVID-19 and Other Infectious Disease Vaccines. LIAS Working Paper Series. 2021. doi:10.29311/lwps.202153849
BibTeX
@article{Bayliss2021,
author = {Bayliss, Christopher D and Gies, Lieve and Pareek, Manish},
title = {UniCoVac Position Paper: Considerations for University Campus-Based Programmes for COVID-19 and Other Infectious Disease Vaccines},
journal = {LIAS Working Paper Series},
year = {2021},
doi = {10.29311/lwps.202153849}
}
EUVIMED